Illumina Ventures Seeks $300M for New Fund

Illumina Ventures Is Seeking $300 Million for New Fund, Filing Shows

The document states that Nicholas Naclerio, founding partner of Illumina Ventures, will manage Illumina Innovation Fund III, which has not yet sold any shares.

Illumina Ventures Invests in Genomics and Precision Health Startups, Raising $230 Million for Its First Fund in 2017. Its Portfolio Includes Arima Genomics, Broken String Biosciences, Delfi Diagnostics, DNAScript, Stilla Technologies, Tagomics, and Twist Bioscience.

This investment firm participated in Illumina's Genomics Accelerator Program last year.

Illumina recently acquired Fluent BioSciences, a single-cell sequencing startup that also received investment from Illumina Ventures.